GSGajanan Sonawane

Gajanan Sonawane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gajanan Sonawane has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced Cytotoxicity of Aqueous Aloe –Silver Nanoparticles Against Human Glioma U‐87 MG Cell Line

    by Neha Saini, Gajanan Sonawane, Kyunghee Yun, Hyeshin Hwang, Kyungmin Kim, Bumho Yoo, Smita Zinjarde, Atul Kulkarni

    The heterogeneity of glioblastoma and recurrence pose a major threat to the life of brain cancer patients. The failure of the current therapeutic regime in preventing its recurrence leads to a growing need for effective cancer treatments with lesser side effects. Previous studies have shown the potential of plants extract to synthesize silver nanoparticles (AgNPs) against U‐87 MG cell line. However, the need for optimum sized and effective nanoparticles is still not fulfilled. Hence, the current work aimed to utilize size controlled bioavailable AgNPs capped with Aloe barbadensis (aqueous extracts) and study their effectiveness against U‐87 MG cells. Two different concentrations of Aloe vera extract (ALE) viz. ALE1 and ALE2, were used. Their physiochemistry was characterized via UV–Vis, dynamic light scattering (DLS), FE‐SEM (50–60 nm diameter), and energy dispersive X‐ray (EDX). The observed zeta potentials were −8 and −16 mV for ALE1– and ALE2–AgNPs, respectively. This indicated that ALE2–AgNPs were more stable. Further, the anticancer potency of both ALE–AgNPs at 0, 24, and 48 h was evaluated. MTT‐assay revealed ALE2–AgNPs were more cytotoxic, significantly inhibiting the proliferation of U‐87 MG, indicating their dose‐dependent cytotoxicity. At an effective concentration of ALE2–AgNPs, (i.e., 10 µg/mL) viability of cancer cell line decreased significantly to 40% after 24 h of treatment. In apoptotic analysis pronounced elevation in early apoptotic cells was noted (5.1% and 9.9% for ALE1– and ALE2–AgNPs, respectively). The significant cytotoxicity and observed apoptosis induction shows ALE–AgNPs’s therapeutic potential against glioblastoma and aqueous extract shows its high biocompatibility, thus having significant probability to be translated in clinical settings.